B cells and B cell directed therapies in CNS inflammation

B08

B cells are an important therapeutic target in MS. While anti-CD20 therapy (depleting B cells) is beneficial in MS, targeting the B cell survival factors B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) with atacicept worsened MS. The reasons for this apparent paradox are unclear, but indicate that the BAFF-APRIL system influences MS in a way that has not yet been understood. We aim to investigate the molecular and cellular basis of mechanism of action of different B cell directed therapies that are currently in use or being developed. In detail, we intend to analyze effects of different B cell directed therapies in peripheral and intrathecal compartments both in MS patients and in B cell dependent animal models including a spontaneous disease model featuring formation of autoantibodies and a Th17 adoptive transfer model featuring formation of submeningeal ectopic lymphoid follicles. These questions will guide our research::

    1. Why did blocking of BAFF and APRIL by atacicept worsen MS?
    2. What are the mechanistic details of anti-CD20 therapy?
    3. Inhibition of Bruton’s Tyrosine Kinase (BTK) is a promising novel therapeutic strategy in MS. How does the inhibition of BTK influence neuroinflammation?

 

 

 

 

 

 

 

 

 

 

 

Laurent et al., Nat Commun., 2015

 

Principal Investigators:

Prof. Dr. med. Edgar Meinl
Institut für klinische Neuroimmunologie
LMU München
edgar.meinl@med.uni-muenchen.de

Dr. rer nat. Anneli Peters
Institut für klinische Neuroimmunologie
LMU München
anneli.peters@med.uni-muenchen.de

News

Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more
Wed, 20/01/2021
A new study on neurological manifestations of severe COVID-19 reveals nervous system immune deficiency
Patients suffering from COVID-19 can develop concomitant and long-term symptoms in their nervous system. The most common symptom in this context is the loss of the sense of smell and taste, while more severe symptoms such as stroke, cerebral seizures, or meningitis are possible. A team of scientists from the medical faculties at the Universities […]...more